losartan has been researched along with allopurinol in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.41) | 18.2507 |
| 2000's | 15 (55.56) | 29.6817 |
| 2010's | 9 (33.33) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Freel, RW; Hatch, M; Shahinfar, S; Vaziri, ND | 1 |
| Ball, EV; Jones, RE | 1 |
| Hada, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T | 2 |
| Chen, Q; Feng, L; Gordon, KL; Han, L; Johnson, RJ; Kanellis, J; Kang, DH; Lan, HY; Mazzali, M; Nakagawa, T; Watanabe, S; Xia, YY | 1 |
| Takagi, K; Tsutani, H | 1 |
| Jeppsson, B; Menger, MD; Riaz, AA; Sato, T; Schramm, R; Thorlacius, H; Wang, Y | 1 |
| Bomalaski, JS; Clark, MA | 1 |
| Raizada, MK; Sellers, KW; Sumners, C; Sun, C | 1 |
| Drexler, H; Fischer, D; Landmesser, U; Manes, C; Mueller, M; Preuss, C; Sorrentino, S; Spiekermann, S | 1 |
| Gironacci, MM; Peña, C; Polizio, AH; Tomaro, ML | 1 |
| Perez-Ruiz, F | 1 |
| Gerster, JC | 1 |
| Arias-Santiago, S; Husein-Elahmed, H; Orgaz-Molina, J; Soriano-Hernández, MI | 1 |
| Dawson, J; Walters, M | 1 |
| Bates, ML; Dopp, JM; Morgan, BJ; Rio, RD; Wang, Z | 1 |
| Chen, AD; Chen, Q; Kang, YM; Li, YH; Qiu, Y; Wang, JJ; Ye, C; Zheng, F; Zhu, GQ | 1 |
5 review(s) available for losartan and allopurinol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Typing of hypouricemia (uric acid clearance)].
Topics: Allopurinol; Creatinine; Humans; Inappropriate ADH Syndrome; Kidney Diseases; Kidney Tubules; Losartan; Metabolic Clearance Rate; Purine-Nucleoside Phosphorylase; Purine-Pyrimidine Metabolism, Inborn Errors; Uric Acid; Xanthine Oxidase | 2003 |
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Topics: Allopurinol; Amlodipine; Clinical Trials as Topic; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Losartan; Pyrazoles; Thiazoles; Treatment Outcome; Urate Oxidase; Uric Acid; Xanthine Oxidase | 2004 |
[Involvement of the foot in metabolic diseases].
Topics: Achilles Tendon; Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Apatites; Chondrocalcinosis; Colchicine; Fenofibrate; Foot Diseases; Gout; Gout Suppressants; Hallux; Hemochromatosis; Humans; Hypercholesterolemia; Hyperostosis, Diffuse Idiopathic Skeletal; Hypolipidemic Agents; Losartan; Radiography; Renal Dialysis; Time Factors; Xanthomatosis | 2007 |
Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Losartan; Risk Factors; Uric Acid; Xanthine Oxidase | 2006 |
22 other study(ies) available for losartan and allopurinol
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biological Transport; Biphenyl Compounds; Chlorides; Colon; Homeostasis; Imidazoles; Intestinal Absorption; Kidney; Kidney Failure, Chronic; Losartan; Male; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Tetrazoles; Urate Oxidase; Uric Acid; Xanthine Oxidase | 1996 |
Gout: beyond the stereotype.
Topics: Aged; Algorithms; Allopurinol; Chronic Disease; Diagnosis, Differential; Female; Gout; Gout Suppressants; Humans; Hypertension; Losartan; Male; Middle Aged; Oxypurinol; Urate Oxidase; Virus Diseases | 1999 |
Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases.
Topics: Adult; Allopurinol; Angiotensin Receptor Antagonists; Creatinine; Humans; Kidney; Losartan; Male; Metabolic Clearance Rate; Middle Aged; Oxypurinol; Purines; Renin; Renin-Angiotensin System; Xanthines | 2000 |
Effect of losartan and furosemide on the urinary excretion of oxypurinol and uric acid.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Proteins; Diuretics; Furosemide; Humans; Losartan; Male; Middle Aged; Oxypurinol; Uric Acid; Xanthine Oxidase | 2000 |
Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.
Topics: Administration, Oral; Allopurinol; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Arterioles; Benzofurans; Blood Pressure; Diuretics; Enalapril; Hydrochlorothiazide; Hypertension; Kidney; Losartan; Male; Muscle, Smooth, Vascular; Oxonic Acid; Rats; Rats, Sprague-Dawley; Sodium Chloride Symporter Inhibitors; Sodium Chloride, Dietary; Uric Acid; Uricosuric Agents; Vascular Diseases | 2002 |
Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon.
Topics: Allopurinol; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Capillaries; Captopril; Cell Adhesion; Chemokines; Chemotaxis, Leukocyte; Colon; Constriction; Disease Models, Animal; Endothelium, Vascular; Enzyme Induction; Gene Expression Regulation; Inflammation; Ischemia; Leukocyte Count; Leukocytes; Losartan; Male; Mesenteric Artery, Superior; Mice; Mice, Inbred C57BL; Mice, Knockout; P-Selectin; Reactive Oxygen Species; Reperfusion Injury; Superoxide Dismutase | 2004 |
NAD(P)H oxidase inhibition attenuates neuronal chronotropic actions of angiotensin II.
Topics: Action Potentials; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Brain Stem; Calcium Signaling; Catalase; Cells, Cultured; Cyclic N-Oxides; Delayed Rectifier Potassium Channels; Drinking Behavior; Glycoproteins; Heart Rate; Hypothalamus; Imidazoles; Injections, Intraventricular; Ion Channel Gating; Losartan; Male; NADPH Oxidases; Neurons; Polyethylene Glycols; Potassium Channels, Voltage-Gated; Pyridines; Rats; Rats, Inbred WKY; Reactive Oxygen Species; Spin Labels; Telemetry; Xanthine; Xanthine Oxidase | 2005 |
Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease.
Topics: Aged; Allopurinol; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cattle; Cells, Cultured; Coronary Circulation; Coronary Disease; Endothelial Cells; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Female; Humans; Losartan; Male; Middle Aged; NADPH Oxidases; Oxypurinol; Superoxides; Vasodilation; Xanthine Oxidase | 2007 |
Angiotensin-(1-7) blocks the angiotensin II-stimulated superoxide production.
Topics: Acetophenones; Allopurinol; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Drug Antagonism; Enzyme Inhibitors; Imidazoles; In Vitro Techniques; Indomethacin; Losartan; Male; NADH, NADPH Oxidoreductases; NG-Nitroarginine Methyl Ester; Onium Compounds; Peptide Fragments; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Superoxides | 2007 |
New treatments for gout.
Topics: Allopurinol; Ascorbic Acid; Female; Fenofibrate; Gout; Gout Suppressants; Humans; Losartan; Male; Sensitivity and Specificity; Urate Oxidase; Uric Acid | 2007 |
[Angioedema due to losartan].
Topics: Aged; Allopurinol; Angioedema; Angiotensin II Type 2 Receptor Blockers; Bradykinin; Diphenhydramine; Humans; Losartan; Male; Methylprednisolone | 2011 |
Oxidative stress augments chemoreflex sensitivity in rats exposed to chronic intermittent hypoxia.
Topics: Acetophenones; Allopurinol; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Antioxidants; Body Weight; Carbon Dioxide; Carotid Sinus; Catecholamines; Chemoreceptor Cells; Free Radical Scavengers; Heart Rate; Hypoxia; Losartan; Male; Oxidative Stress; Oxygen Consumption; Plethysmography; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Regression Analysis; Respiration; Tidal Volume; Time Factors; Tyrosine | 2016 |
Angiotensin Type 1 Receptors and Superoxide Anion Production in Hypothalamic Paraventricular Nucleus Contribute to Capsaicin-Induced Excitatory Renal Reflex and Sympathetic Activation.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Acetophenones; Acetylcysteine; Allopurinol; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Capsaicin; Captopril; Ditiocarb; Kidney; Losartan; Male; NADPH Oxidases; Onium Compounds; Paraventricular Hypothalamic Nucleus; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Reflex; Superoxides | 2020 |